Jana Jurečeková1, Eva Babušíková2, Monika Kmeťová2, Ján Kliment3, Dušan Dobrota2. 1. Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic. jurecekova@jfmed.uniba.sk. 2. Department of Medical Biochemistry, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic. 3. Department of Urology, Jessenius Faculty of Medicine and University Hospital Martin, Comenius University in Bratislava, Martin, Slovak Republic.
Abstract
PURPOSE: The main purpose of the study was to evaluate the effect of two polymorphisms in the estrogen receptor alpha, rs2077647 and rs3798577, on the development of prostate cancer, their correlation with selected clinical characteristics, as well as consideration of potential interactions between four estrogen receptor alpha polymorphisms (rs2077647, rs3798577, PvuII, XbaI). METHODS: The study was performed using 395 patients with histologically verified prostate cancer and 253 healthy male controls. RESULTS: The CC genotype of rs2077647 was significantly associated with prostate cancer (OR = 1.61). No association was found between rs3798577 polymorphism and prostate cancer. After stratification of patients according to the age at diagnosis and Gleason score, we observed significant correlation between rs2077647 polymorphism and prostate cancer risk in patients diagnosed before the age of 60 as well as patients with Gleason score <7, while rs3798577 was significantly associated with prostate cancer risk development in patients older than 60 and with Gleason score ≥7. Double analysis of each combination of four studied polymorphisms showed that presence of at least three variant alleles was associated with prostate cancer risk in all combinations, while each containing rs3798577 was significantly associated with development of high-grade carcinomas. CONCLUSIONS: The present study suggests that rs2077647 polymorphism may be a risk factor for prostate cancer especially in patients diagnosed before the age of 60, while rs3798577 polymorphism could probably serve rather as promoting factor in combination with other polymorphisms in estrogen receptor alpha contributing preferably to development of high-grade carcinomas.
PURPOSE: The main purpose of the study was to evaluate the effect of two polymorphisms in the estrogen receptor alpha, rs2077647 and rs3798577, on the development of prostate cancer, their correlation with selected clinical characteristics, as well as consideration of potential interactions between four estrogen receptor alpha polymorphisms (rs2077647, rs3798577, PvuII, XbaI). METHODS: The study was performed using 395 patients with histologically verified prostate cancer and 253 healthy male controls. RESULTS: The CC genotype of rs2077647 was significantly associated with prostate cancer (OR = 1.61). No association was found between rs3798577 polymorphism and prostate cancer. After stratification of patients according to the age at diagnosis and Gleason score, we observed significant correlation between rs2077647 polymorphism and prostate cancer risk in patients diagnosed before the age of 60 as well as patients with Gleason score <7, while rs3798577 was significantly associated with prostate cancer risk development in patients older than 60 and with Gleason score ≥7. Double analysis of each combination of four studied polymorphisms showed that presence of at least three variant alleles was associated with prostate cancer risk in all combinations, while each containing rs3798577 was significantly associated with development of high-grade carcinomas. CONCLUSIONS: The present study suggests that rs2077647 polymorphism may be a risk factor for prostate cancer especially in patients diagnosed before the age of 60, while rs3798577 polymorphism could probably serve rather as promoting factor in combination with other polymorphisms in estrogen receptor alpha contributing preferably to development of high-grade carcinomas.
Entities:
Keywords:
Estrogen receptor alpha; Gene; Polymorphism; Prostate cancer
Authors: Sarah K Holt; Erika M Kwon; Rong Fu; Suzanne Kolb; Ziding Feng; Elaine A Ostrander; Janet L Stanford Journal: Prostate Date: 2012-05-01 Impact factor: 4.104
Authors: Javier Hernández; Ivana Balic; Teresa L Johnson-Pais; Betsy A Higgins; Kathleen C Torkko; Ian M Thompson; Robin J Leach Journal: J Urol Date: 2006-02 Impact factor: 7.450
Authors: Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-03 Impact factor: 4.254